Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination
- 521 Downloads
The purpose of these studies was to enhance mucosal and systemic antibody production in response to increased local residence time of a whole inactivated influenza virus administered as a dry powder nasal vaccine formulation. Spray-freeze-drying (SFD) particles suitable for nasal delivery were characterized for physico-chemical properties and stability. Mucoadhesive compounds (MA) were characterized for their effects on nasal residence time of vaccine powders in rats compared with published in vitro data and elicited immune responses. SFD particles (D50=26.9µm) were spherical with a specific surface area of 1.25 m2/g. Thermal analysis indicated SFD powders were amorphous and demonstrated improved stability with respect to liquid formulations under various storage conditions. In vitro physico-chemical studies and in vivo scintigraphic imaging experiments indicated sodium alginate (SA) and carboxymethylcellulose-high molecular weight (CMC-HMW) powder formulations most significantly increased residence time in Brown Norway rats. Intramuscular delivery provided equivalent serum antibody titers to intranasal (IN) powder without MA, in the presence of CMC-HMW, SA, and hydroxypropyl methylcellulose (HPMC-HMW) after initial dosing and all formulations except IN powder with chitosan after boosting. IN liquid provided equivalent serum antibody titers to all IN powders after the initial vaccination and significantly greater serum antibody titers than IN powder with chitosan after boosting. Trends were consistent between residence time studies and immune response; however, no statistically significant differences between powder and liquid formulations were observed. It was concluded that enhanced serum and mucosal antibody responses were elicited by a dry powder nasal vaccine, specifically, administered in the presence of sodium alginate.
Keywordsintranasal powder influenza vaccine mucoadhesive spray-freeze-drying
Unable to display preview. Download preview PDF.
- 6.Garmise RJ, Mar K, Crowder TM, et al. Formulation of a dry powder influenza vaccine for nasal delivery.AAPS PharmSciTech. 2006;7: article 19.Google Scholar
- 10.Gombotz WR, Healy MS, Brown LR, Auer HE, inventors. Alkermes Controlled Therapeutics, Inc., assignee. Process for producing small particles of biologically active molecules. US patent 6569458. May 27, 2003.Google Scholar
- 22.Martin AN, Bustamante P.Physical Pharmacy: Physical Chemmical Principles in the Pharmaceutical Sciences. Philadelphia, PA: Lea & Febiger; 1993.Google Scholar
- 23.Carstensen JT.Pharmaceutical Principles of Solid Dosage Forms. Lancaster, PA: Technomic Publishing Co.; 1993.Google Scholar
- 24.Carr RL, jr. Evaluating flow properties of solids.Chem Eng. 1965;72:163–168.Google Scholar
- 25.Carr RL, Jr. Classifying flow properties of solids.Chem Eng. 1965;72:69–72.Google Scholar
- 26.Staniforth JN. Powder flow. In: Aulton ME, ed.Pharmaceutics: The Science of Dosage Form Design. 1st ed. New York: Churchill Livingstone; 2002:197–210.Google Scholar
- 29.FDA.US FDA Draft Guidance for Industry. Q1A(R2) Stability Testing of New Drug Substances and Products. Bethesda, MD: USFDA; 2003.Google Scholar
- 30.Pikal MJ. Freeze-drying of proteins. In: Cleland JL, Langer R, eds.Formulation and Delivery of Proteins and Peptides. vol. 5567. Washington, DC: ACS Symposium Series; 1994:120–133.Google Scholar
- 32.Carpenter JF, Chang BS. Lyophilization of protein pharmaceuticals. In: Avis KE, Wu VL, eds.Biotechnology and Biopharmaceutical Manufacturing, Processing, and Preservation. Buffalo Grove, IL: Interpharm Press; 1996:199–264.Google Scholar
- 34.Garmise RJ, Hickey AJ. In vitro evaluation of mucoadhesive compounds for use in a dry powder nasal vaccine. Paper presented at: Respiratory Drug Delivery X; April 23–27, 2006; boca Raton, FL.Google Scholar